A Phase I, Single-Centre, Open-Label, Randomized, One-Sequence Crossover, Three-Group Study to Evaluate the Effect of Ketoconazole, Ritonavir and Erythromicin on the Safety and Pharmacokinetics of Avanafil (TA-1790) in Healthy Male Subjects.

Trial Profile

A Phase I, Single-Centre, Open-Label, Randomized, One-Sequence Crossover, Three-Group Study to Evaluate the Effect of Ketoconazole, Ritonavir and Erythromicin on the Safety and Pharmacokinetics of Avanafil (TA-1790) in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2009

At a glance

  • Drugs Avanafil; Erythromycin; Ketoconazole; Ritonavir
  • Indications Bacterial infections; Erectile dysfunction; HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors VIVUS
  • Most Recent Events

    • 04 Dec 2009 Actual number of patients (44) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top